Skinhealth Systems Inc. (SKIN) Stock Price & Analysis

Skinhealth Systems Inc. (SKIN) fell 0.06% to USD 0.63 as of June 10, 2026 at 02:24 UTC, according to Nexqual real-time market data.

SKIN last closed at USD 0.63; the session ranged USD 0.62–0.66 on volume of 440,635 shares. Market capitalization is $82.13M, with a 52-week range of USD 0.55–2.69 (NCM). Source: Nexqual, June 10, 2026 at 02:24 UTC.

Key Statistics (as of June 10, 2026 at 02:24 UTC)

Technical Analysis (SKIN)

Nexqual's technical model rates SKIN "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:24 UTC.

Analyst Ratings (SKIN)

Wall Street analysts rate SKIN "None" based on 6 analysts, with a mean price target of USD 1.34 (range USD 1–2), per Nexqual as of June 10, 2026 at 02:24 UTC.

Earnings (SKIN)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:24 UTC.

Financials & Fundamentals (SKIN)

Source: Nexqual, June 10, 2026 at 02:24 UTC.

Financial Health Score (SKIN)

Nexqual rates Skinhealth Systems Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:24 UTC.

Ownership (SKIN)

Source: Nexqual, June 10, 2026 at 02:24 UTC.

Leadership (SKIN)

Skinhealth Systems Inc. is led by Pedro Malha (age 53), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:24 UTC.

Major Backers & Investors (SKIN)

Notable institutional backers of Skinhealth Systems Inc. include Capricorn Fund Managers Ltd, FMR, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 02:24 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:24 UTC.

From Skinhealth Systems Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• Anchored by Hydrafacial, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp powered by Keravive, the Company combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide.
• The table below summarizes the Consumables product offerings: The Hydrafacial Experience A Hydrafacial treatment is a noninvasive hydradermabrasion process that utilizes a patented Delivery System to cleanse, extract, and hydrate the skin with proprietary solutions and serums.
• Our patent portfolio covers key aspects of certain products, systems, and designs, including several issued U.S. patents directed to features of the Hydrafacial MD® liquid-based skin exfoliation system.
• Class I includes devices 14 with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA's General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation ("QSR"); facility registration and product listing; reporting of adverse medical events; and truthful and non-misleading labeling, advertising, and promotional materials.

Partnerships

• We collaborate with our suppliers and contract manufacturers to ensure that they follow our established product design specifications and quality assurance programs.
• To support the "pull" side of our products, we are investing in tactics to drive consumer demand such as gift-with-purchase promotions, in-office events, targeted paid campaigns, and regional experiences such as influencer spa days conducted in partnership with key accounts and local influencers to promote both the Hydrafacial brand and product offerings.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:24 UTC. This page is informational and not investment advice.